Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seasonal SARS-CoV-2 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Epidermal
01
Overview
The seasonal SARS-CoV-2 DNA vaccine is a preclinical-stage nucleic acid vaccine candidate developed by Orlance. It is designed to provide seasonal protection against COVID-19 by expressing SARS-CoV-2 antigens in vivo to induce both systemic and mucosal immunity. The vaccine utilizes Orlance's proprietary MACH-1 epidermal gene-gun delivery system, which delivers microparticle-coated DNA directly into the skin's epidermis. This delivery method is intended to target antigen-presenting cells efficiently, potentially offering a stable, needle-free alternative to traditional liquid-based vaccines.
- Other names
- SARS-CoV-2 DNA vaccineSARS-CoV2 DNA vaccineSARS-CoV 2 DNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on seasonal SARS-CoV-2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seasonal SARS-CoV-2 DNA vaccine.